Charles River Laboratories International, Inc. (CRL) stock
CRLNYSEServices-Commercial Physical & Biological ResearchFiscal year ends December 27
Financials through Q2 FY2026, quarter ended Jun 27, 2026Last filing: 10-Q on Nov 4, 2026Score 6/30225% above fair value
$332.16−3.36 (-1.00%)
Close on Nov 17, 2026Market cap $15.86BP/E –Yield –
Charles River Laboratories International cash
Cash and short-term investments held at the end of each period.
Charles River Laboratories International's cash was $192.03M at Jun 27, 2026. For fiscal 2025 it was $213.77M, up 4.0% from the year before. Over ten years it grew 4.3% a year on average. The highest annual figure on record is $284.48M in fiscal 2023.
Annual cash
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 27, 2025 | $213.77M | +4.0% |
| FY2024 | Dec 28, 2024 | $205.57M | -27.7% |
| FY2023 | Dec 30, 2023 | $284.48M | +17.9% |
| FY2022 | Dec 31, 2022 | $241.21M | -2.5% |
| FY2021 | Dec 25, 2021 | $247.38M | +5.7% |
| FY2020 | Dec 26, 2020 | $234.14M | -2.8% |
| FY2019 | Dec 28, 2019 | $240.99M | +21.6% |
| FY2018 | Dec 29, 2018 | $198.20M | +1.7% |
| FY2017 | Dec 30, 2017 | $194.82M | +57.5% |
| FY2016 | Dec 31, 2016 | $123.67M | -12.0% |
| FY2015 | Dec 26, 2015 | $140.48M | -13.6% |
| FY2014 | Dec 27, 2014 | $162.58M | -2.7% |
| FY2013 | Dec 28, 2013 | $167.09M | +43.5% |
| FY2012 | Dec 29, 2012 | $116.47M | +56.8% |
| FY2011 | Dec 31, 2011 | $74.26M | -60.7% |
| FY2010 | Dec 25, 2010 | $188.99M | +3.5% |
| FY2009 | Dec 26, 2009 | $182.57M | -25.0% |
| FY2008 | Dec 27, 2008 | $243.59M | +8.0% |
| FY2007 | Dec 29, 2007 | $225.45M | – |
Quarterly cash
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 27, 2026 | $192.03M | +5.0% |
| Q1 FY2026 | Mar 28, 2026 | $191.83M | -16.4% |
| Q4 FY2025 | Dec 27, 2025 | $213.77M | +4.0% |
| Q3 FY2025 | Sep 27, 2025 | $207.10M | -1.5% |
| Q2 FY2025 | Jun 28, 2025 | $182.82M | +2.0% |
| Q1 FY2025 | Mar 29, 2025 | $229.36M | -29.9% |
| Q4 FY2024 | Dec 28, 2024 | $205.57M | -27.7% |
| Q3 FY2024 | Sep 28, 2024 | $210.17M | +33.7% |
| Q2 FY2024 | Jun 29, 2024 | $179.21M | -14.2% |
| Q1 FY2024 | Mar 30, 2024 | $327.04M | +56.6% |
| Q4 FY2023 | Dec 30, 2023 | $284.48M | +17.9% |
| Q3 FY2023 | Sep 30, 2023 | $157.17M | -20.3% |
| Q2 FY2023 | Jul 1, 2023 | $208.78M | +0.3% |
| Q1 FY2023 | Apr 1, 2023 | $208.89M | -14.0% |
| Q4 FY2022 | Dec 31, 2022 | $241.21M | -2.5% |
| Q3 FY2022 | Sep 24, 2022 | $197.13M | -7.7% |
| Q2 FY2022 | Jun 25, 2022 | $208.22M | -7.0% |
| Q1 FY2022 | Mar 26, 2022 | $242.93M | -47.9% |
| Q4 FY2021 | Dec 25, 2021 | $247.38M | +5.7% |
| Q3 FY2021 | Sep 25, 2021 | $213.57M | -12.4% |
| Q2 FY2021 | Jun 26, 2021 | $224.01M | -44.4% |
| Q1 FY2021 | Mar 27, 2021 | $466.44M | +24.9% |
| Q4 FY2020 | Dec 26, 2020 | $234.14M | -2.8% |
| Q3 FY2020 | Sep 26, 2020 | $243.84M | +47.2% |
| Q2 FY2020 | Jun 27, 2020 | $402.95M | +100.0% |
| Q1 FY2020 | Mar 28, 2020 | $373.37M | +193.5% |
| Q4 FY2019 | Dec 28, 2019 | $240.99M | +21.6% |
| Q3 FY2019 | Sep 28, 2019 | $165.61M | +14.9% |
| Q2 FY2019 | Jun 29, 2019 | $201.48M | +4.3% |
| Q1 FY2019 | Mar 30, 2019 | $127.22M | -33.2% |
| Q4 FY2018 | Dec 29, 2018 | $198.20M | +1.7% |
| Q3 FY2018 | Sep 29, 2018 | $144.10M | -6.4% |
| Q2 FY2018 | Jun 30, 2018 | $193.20M | +38.1% |
| Q1 FY2018 | Mar 31, 2018 | $190.32M | +40.6% |
| Q4 FY2017 | Dec 30, 2017 | $194.82M | +57.5% |
| Q3 FY2017 | Sep 30, 2017 | $153.97M | +45.6% |
| Q2 FY2017 | Jul 1, 2017 | $139.94M | – |
| Q1 FY2017 | Apr 1, 2017 | $135.40M | – |
| Q4 FY2016 | Dec 31, 2016 | $123.67M | – |
| Q3 FY2016 | Sep 24, 2016 | $105.72M | – |
See a number that looks wrong?